ResMed delivered a strong Q2 FY2026 with revenue of $1.42 billion, representing 11% headline growth (9% constant currency). GAAP EPS grew 16% and operating profit increased 19%, driven by 310 basis points of gross margin expansion (per CEO) and solid double-digit growth across masks and devices. Management highlighted a major strategic shift regarding GLP-1 drugs, presenting claims data from 1.95 million patients showing that GLP-1 users are 10-11% more likely to start CPAP therapy and demonstrate a 6% higher resupply rate at 3 years, effectively classifying the trend as a 'tailwind' rather than a headwind. Operational excellence remains a focus, with the CEO challenging the supply chain to deliver double-digit basis point margin improvements annually through 2030 and investing in U.S. manufacturing ('Made in America' strategy). The company raised its share repurchase guidance to over $600 million for FY2026 and reiterated its confidence in double-digit growth for the mask category.
| Metric | Value | Change |
|---|---|---|
| Revenue | $1.42 Billion | +11% (Headline), +9% (CC) |
| GAAP EPS | Not specified | +16% |
| Gross Margin | 32.3% (Note: Transcript text) | +110 bps (YoY) |
| Operating Margin | 36.3% | +230 bps |
| Net Income | Not specified | +15% |
| Cash Balance | $1.4 Billion | N/A |
| Net Cash | $753 Million | N/A |
| U.S. Masks & Other Growth | N/A | +16% |
| Global Device Growth | N/A | +11% (CC) |
Management is aggressively leveraging the 'GLP-1 tailwind' to drive growth. New claims data tracking 1.95 million patients revealed that patients on GLP-1 therapies are 10-11% more likely to initiate CPAP therapy and, crucially, maintain a 6% higher resupply rate at 3 years compared to non-GLP-1 patients. This data supports a strategic pivot where ResMed educates PCPs to prescribe combination therapies (GLP-1 + CPAP), effectively using Big Pharma's marketing spend to fuel their own patient funnel.
ResMed is executing a 'Made in America' supply chain strategy to mitigate geopolitical risks and improve logistics. The company is expanding its Calabasas, California plant (doubling U.S. manufacturing capacity) and building a new distribution center in Indiana set to open in calendar year 2027. This initiative aims to enable 2-day shipping to 90% of U.S. customers and positions the company to offer the only 'Made in America' CPAP and mask systems, a significant competitive differentiator.
The company is deepening its investment in the 'top of the funnel' through primary care physician (PCP) education and digital acquisitions. ResMed's CME programs have been completed 60,000 times (up 50% sequentially), with 77% of participating providers intending to change clinical practices. Acquisitions like VirtuOx (home sleep testing) and Somnoware (practice management) are being integrated to create a seamless 'digital concierge' pathway that captures patients generated by Big Tech wearables and Big Pharma advertising.
Product innovation is focused on 'changing the basis of competition' through comfort and AI. The launch of the F30i Comfort and Clear fabric masks is designed to drive adoption through superior comfort, while the FDA-cleared 'Comfort Match' AI feature within the myAir platform aims to improve long-term adherence by personalizing therapy settings. These moves aim to lock patients into the ResMed ecosystem, increasing switching costs and adherence rates.
There is a significant discrepancy in the reported financial metrics within the transcript. CEO Mick Farrell stated the team delivered '310 basis points of year-over-year gross margin expansion,' while CFO Brett Sandercock reported gross margin was '32.3%... increased by 110 basis points year-over-year.' Furthermore, the CFO guided for full-year gross margin of '62% to 63%,' suggesting the 32.3% figure may be a typographical error for 62.3%. This inconsistency creates confusion regarding the true margin performance and requires clarification.
Selling, General, and Administrative (SG&A) expenses grew 15% on a headline basis, outpacing revenue growth of 11%. While management attributed this to the VirtuOx acquisition and holiday marketing promotions (Singles Day, Black Friday), the persistent investment in demand generation requires careful monitoring to ensure it translates into sustainable revenue growth rather than just elevated operating leverage.
The Residential Care Software (RCS) segment continues to lag, growing only 5% on a constant currency basis. Management acknowledged 'ongoing challenges in our senior living and long-term care vertical' and indicated they are managing the portfolio to return to high single-digit growth by fiscal year 2027. This segment remains a drag on the overall software growth narrative.
The effective tax rate increased to 21.1% from 18% in the prior year due to global minimum tax legislation. Management guided for a rate of 21-23% for fiscal year 2026, which represents a structural headwind to net income growth that was not present in previous periods.
Overall: Management exhibited a highly confident and enthusiastic demeanor throughout the call. CEO Mick Farrell was particularly bullish, repeatedly emphasizing 'operational excellence' and 'innovation,' while aggressively reframing the GLP-1 narrative as a significant growth driver. There was a notable lack of defensiveness regarding competition, even with Philips' potential return, focusing instead on internal execution and ecosystem advantages.
Confidence: HIGH - Management backed their confidence with specific, granular data points (e.g., 1.95M patient claims, 60,000 CME completions, 310 bps margin expansion). They provided clear strategic rationale for investments and offered definitive guidance on capital allocation (> $600M buybacks). The tone was assertive in dismissing risks (GLP-1 headwinds, Philips re-entry).
62% to 63%
19% to 20%
6% to 7%
21% to 23%
More than $600 million
Mid-single-digit growth
Hedging & Uncertainty: Management used very little hedging regarding core operational performance, using definitive phrases like 'incredible result' and 'strong quarter.' However, some hedging appeared around the quantification of new growth drivers, specifically regarding GLP-1s and Big Tech. CEO Mick Farrell stated, 'We don't fully understand the psychology' behind the GLP-1 correlation and noted regarding quantification, 'We're not prepared to publicly talk about it yet.' This suggests confidence in the trend's existence but caution in pinning exact financial attribution to it this early.
The thesis that this could be a headwind is completely gone. It's a tailwind. - Michael Farrell, CEO
We're in mile 1 of the marathon. - Michael Farrell, CEO
I don't really look back to the #2, 3 or 4 competitor... I look forward. - Michael Farrell, CEO
I have challenged our supply chain team to deliver double-digit basis points improvement in gross margin every year through 2030. - Michael Farrell, CEO
We're seeing that the motivation of these patients lasts and even accelerates over time. - Michael Farrell, CEO
We expect strong adoption of these masks over time. - Michael Farrell, CEO
Analyst Sentiment: Analysts were highly engaged and broadly positive, focusing heavily on the sustainability of the GLP-1 tailwind and the mechanics behind the strong U.S. mask growth. There was skepticism regarding the ability to maintain the 16% mask growth, which management addressed by discussing seasonality and ROI-driven marketing.
Management Responses: Management responses were detailed and data-rich, particularly regarding the GLP-1 patient cohort data. They were transparent about the lumpiness of device growth in ex-U.S. markets but firm on their long-term strategy. They effectively deflected concerns about Philips' re-entry by emphasizing their own ecosystem advantages.
Deep dive into GLP-1 impact: Analysts sought to quantify the 'tailwind' and understand if it would sustain. Management provided 3-year adherence data showing increased resupply rates.
U.S. Mask Growth: Questions on the 16% growth rate, specifically the contribution from VirtuOx acquisition and new product launches (F30i). Management confirmed double-digit growth even excluding VirtuOx.
SG&A Leverage: Analysts questioned why SG&A growth outpaced revenue. Management explained it was due to VirtuOx integration and specific holiday marketing campaigns (Singles Day, Black Friday).
Philips Re-entry: Analysts asked about the timing and impact of Philips returning to the U.S. market. Management dismissed the threat, stating they are 'not fearful' and focused on their own innovation.
PCP Channel Effectiveness: Questions on the ROI of educating Primary Care Physicians. Management cited the 50% increase in CME completions as a leading indicator of success.
ResMed is successfully executing on a strategy to leverage external macro tailwinds (GLP-1s, Wearables) to drive internal growth. The company has effectively debunked the bear thesis that weight-loss drugs would destroy CPAP demand, instead proving they act as a catalyst for patient initiation and adherence. Operationally, the company is an 'innovation machine' with a clear path to margin expansion through supply chain excellence and 'Made in America' initiatives. The digital ecosystem (myAir, Brightree, AirView) creates a wide moat that competitors like Philips cannot easily replicate. With a strong balance sheet, aggressive share buybacks, and a clear 'mile 1 of the marathon' growth runway, RMD remains a compelling long-term holding.
CPAP products were excluded from the CMS competitive bidding program for the first time in 15 years, removing a major overhang on pricing and reimbursement for U.S. Medicare patients.
Management expects continued tariff relief for medical supplies under the 'Nairobi protocol,' mitigating risks from ongoing trade investigations.
Convergence of Big Tech (Apple/Samsung sleep apnea detection) and Big Pharma (GLP-1s) is driving unprecedented awareness and diagnosis rates, creating a 'rising tide' for the sleep health sector.